alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer's disease: Methods of scan analysis

Emma Terriere; Mike Sharman; Claire Donaghey; Lucie Herrmann; Jane Lonie; Marion Strachan; Nadine Dougall; Jonathan Best; Klaus P. Ebmeier; Sally Pimlott; Jim Patterson; David Wyper

doi:10.1007/s11064-007-9517-4

alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer's disease: Methods of scan analysis

Emma Terriere, Mike Sharman, Claire Donaghey, Lucie Herrmann, Jane Lonie, Marion Strachan, Nadine Dougall, Jonathan Best, Klaus P. Ebmeier, Sally Pimlott, Jim Patterson, David Wyper

Research output: Contribution to journal › Article › peer-review

Abstract

Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand I-123-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.

Original language	English
Pages (from-to)	643-651
Number of pages	9
Journal	Neurochemical Research
Volume	33
Issue number	4
DOIs	https://doi.org/10.1007/s11064-007-9517-4
Publication status	Published - Apr 2008

Access to Document

10.1007/s11064-007-9517-4

Cite this

@article{99a0ee5a135b4ffdaa41a892d2cd0fcd,

title = "alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer's disease: Methods of scan analysis",

abstract = "Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand I-123-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.",

author = "Emma Terriere and Mike Sharman and Claire Donaghey and Lucie Herrmann and Jane Lonie and Marion Strachan and Nadine Dougall and Jonathan Best and Ebmeier, {Klaus P.} and Sally Pimlott and Jim Patterson and David Wyper",

year = "2008",

month = apr,

doi = "10.1007/s11064-007-9517-4",

language = "English",

volume = "33",

pages = "643--651",

journal = "Neurochemical Research",

issn = "0364-3190",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer's disease: Methods of scan analysis

AU - Terriere, Emma

AU - Sharman, Mike

AU - Donaghey, Claire

AU - Herrmann, Lucie

AU - Lonie, Jane

AU - Strachan, Marion

AU - Dougall, Nadine

AU - Best, Jonathan

AU - Ebmeier, Klaus P.

AU - Pimlott, Sally

AU - Patterson, Jim

AU - Wyper, David

PY - 2008/4

Y1 - 2008/4

N2 - Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand I-123-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.

AB - Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand I-123-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.

U2 - 10.1007/s11064-007-9517-4

DO - 10.1007/s11064-007-9517-4

M3 - Article

SN - 0364-3190

VL - 33

SP - 643

EP - 651

JO - Neurochemical Research

JF - Neurochemical Research

IS - 4

ER -

alpha 4 beta 2-nicotinic receptor binding with 5-IA in Alzheimer's disease: Methods of scan analysis

Abstract

Access to Document

Fingerprint

Cite this